3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Ruscogenin attenuated tight junction injury and tumor migration in colorectal liver metastasis mice via regulating TRAP1

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The effect of ruscogenin on the colorectal cancer is not clear yet. The study was applied to elucidate the mechanism of ruscogenin on colorectal cancer via regulating tumor necrosis factor receptor related protein 1 (TRAP1).

          Methods

          HCT-116 cells were inoculated under the spleen capsule to establish the colorectal liver metastasis model. The group was divided into control, inoculation model, low dose (5 mg/kg), mediate dose (10 mg/kg), and high dose ruscogenin (20 mg/kg). The body and liver weight of the animals and tumor nodules were recorded. Western blot analysis and immunofluorescence assay were applied to indicate the alternation of tight junction, migration, and proliferation proteins.

          Results

          Following the inoculated with tumor cells, the mice in the inoculation group suffered from liver volume and weight decrease, as well as the increase of liver tumor volume (TV) and weight (TW). The administration of ruscogenin could obviously decrease body weight and increase liver weight in a dose-dependent manner. Meanwhile, 5, 10, 20 mg/kg ruscogenin could reduce the acreage of tumor nodule on liver, while the high dose 20 mg/kg ruscogenin could minimize the growth of tumor nodule. The intervention of ruscogenin could relieve the decreased expression of claudin-5, occludin, and ZO-1. The administration of ruscogenin could relieve the aggravated tight junction injury by the overexpression of TRAP1, while 20 mg/kg ruscogenin could not alleviate the tight junction injury already defused by the TRAP1 antibody in the colorectal cancer mice.

          Conclusions

          Ruscogenin could attenuate the tight junction injury via suppressing TRAP1 in the colorectal cancer mice.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          NCCN Guidelines Insights: Colon Cancer, Version 2.2018

          The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship. These NCCN Guidelines Insights summarize the NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation-positive metastatic colorectal cancer with regimens containing vemurafenib.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Tight Junction Proteins and Signaling Pathways in Cancer and Inflammation: A Functional Crosstalk

            The ability of epithelial cells to organize through cell–cell adhesion into a functioning epithelium serves the purpose of a tight epithelial protective barrier. Contacts between adjacent cells are made up of tight junctions (TJ), adherens junctions (AJ), and desmosomes with unique cellular functions and a complex molecular composition. These proteins mediate firm mechanical stability, serves as a gatekeeper for the paracellular pathway, and helps in preserving tissue homeostasis. TJ proteins are involved in maintaining cell polarity, in establishing organ-specific apical domains and also in recruiting signaling proteins involved in the regulation of various important cellular functions including proliferation, differentiation, and migration. As a vital component of the epithelial barrier, TJs are under a constant threat from proinflammatory mediators, pathogenic viruses and bacteria, aiding inflammation and the development of disease. Inflammatory bowel disease (IBD) patients reveal loss of TJ barrier function, increased levels of proinflammatory cytokines, and immune dysregulation; yet, the relationship between these events is partly understood. Although TJ barrier defects are inadequate to cause experimental IBD, mucosal immune activation is changed in response to augmented epithelial permeability. Thus, the current studies suggest that altered barrier function may predispose or increase disease progression and therapies targeted to specifically restore the barrier function may provide a substitute or supplement to immunologic-based therapies. This review provides a brief introduction about the TJs, AJs, structure and function of TJ proteins. The link between TJ proteins and key signaling pathways in cell proliferation, transformation, and metastasis is discussed thoroughly. We also discuss the compromised intestinal TJ integrity under inflammatory conditions, and the signaling mechanisms involved that bridge inflammation and cancer.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Ruscogenin Attenuates Cerebral Ischemia-Induced Blood-Brain Barrier Dysfunction by Suppressing TXNIP/NLRP3 Inflammasome Activation and the MAPK Pathway

              Ruscogenin, an important steroid sapogenin derived from Ophiopogon japonicus, has been shown to inhibit cerebral ischemic injury. However, its potential molecular action on blood-brain barrier (BBB) dysfunction after stroke remains unclear. This study aimed to investigate the effects of ruscogenin on BBB dysfunction and the underlying mechanisms in middle cerebral artery occlusion/reperfusion (MCAO/R)-injured mice and oxygen–glucose deprivation/reoxygenation (OGD/R)-injured mouse brain microvascular endothelial cells (bEnd.3). The results demonstrated that administration of ruscogenin (10 mg/kg) decreased the brain infarction and edema, improved neurological deficits, increased cerebral brain flow (CBF), ameliorated histopathological damage, reduced evans blue (EB) leakage and upregulated the expression of tight junctions (TJs) in MCAO/R-injured mice. Meanwhile, ruscogenin (0.1–10 µM) treatment increased cell viability and trans-endothelial electrical resistance (TEER) value, decreased sodium fluorescein leakage, and modulated the TJs expression in OGD/R-induced bEnd.3 cells. Moreover, ruscogenin also inhibited the expression of interleukin-1β (IL-1β) and caspase-1, and markedly suppressed the expression of Nucleotide-binding domain (NOD)-like receptor family, pyrin domain containing 3 (NLRP3) and thiredoxin-interactive protein (TXNIP) in vivo and in vitro. Furthermore, ruscogenin decreased reactive oxygen species (ROS) generation and inhibited the mitogen-activated protein kinase (MAPK) pathway in OGD/R-induced bEnd.3 cells. Our findings provide some new insights into its potential application for the prevention and treatment of ischemic stroke.
                Bookmark

                Author and article information

                Journal
                Transl Cancer Res
                Transl Cancer Res
                TCR
                Translational Cancer Research
                AME Publishing Company
                2218-676X
                2219-6803
                March 2021
                March 2021
                : 10
                : 3
                : 1470-1483
                Affiliations
                [1 ]deptKey Laboratory of Modern Preparation of TCM. Ministry of Education , Jiangxi University of Traditional Chinese Medicine , Nanchang, China;
                [2 ]deptDepartment of Pharmacy , The First Affiliated Hospital of Nanchang University , Nanchang, China;
                [3 ]deptDepartment of Neurology , The First Affiliated Hospital of Nanchang University , Nanchang, China;
                [4 ]deptKey Laboratory of Innovation Drug and Efficient Energy-saving Pharmaceutical Equipment , Jiangxi University of Traditional Chinese Medicine , Nanchang, China
                Author notes

                Contributions: Conception and design: Y Lv, F Shao; (II) Administrative support: All authors; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: X Wu, J Chen, F Shao; (V) Data analysis and interpretation: X Wu, J Chen, F Shao; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

                Correspondence to: Feng Shao. Associate Professor, Meiling Avenue, No. 1688, Wanli District, Nanchang 330004, China. Email: shaofeng0729@ 123456163.com .
                [^]

                ORCID: 0000-0002-7976-2643.

                Article
                tcr-10-03-1470
                10.21037/tcr-20-2968
                8797745
                35116472
                2c79e735-f8a4-4f4e-9664-7d395265e3f6
                2021 Translational Cancer Research. All rights reserved.

                Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

                History
                : 30 September 2020
                : 08 January 2021
                Funding
                Funded by: Foundation Project: National Natural Science Foundation of China, China
                Award ID: No: 81760094
                Award ID: 31860276
                Funded by: The Foundation of Jiangxi Provincial Department of Science and Technology Applied research cultivation projects
                Award ID: No. 20181BBG78051
                Award ID: No. 20171BAB215067
                Funded by: The Foundation of Jiangxi Provincial Department of Science and Technology Key Project
                Award ID: No. 20202ACBL206001
                Funded by: Project of Jiangxi health and Family Planning Commission, China
                Award ID: No: 20203114
                Award ID: 20203095
                Award ID: 20181021
                Funded by: Scientific research project of traditional Chinese medicine in Jiangxi Province
                Award ID: No: 2020B0314
                Funded by: Open Project of Key Laboratory of Modern proparation of TCM, Ministry of Education Jiangxi University of Traditional Chinese Medicine
                Award ID: TCM-2019010
                Categories
                Original Article

                ruscogenin,tight junction,migration,colorectal liver metastasis

                Comments

                Comment on this article